UniQure Biopharma B.V.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS5
PHASE 3 / 2-30
RECRUITING2
READOUTS ≤12 MONTHS1
READOUT SLIPPED >6 MO80%
Delay Index: of 5 active trials registered more than a year ago, 4 have moved their primary completion (readout) date by more than 6 months since first registration (median +24.0 months). See all sponsors →
Open UniQure Biopharma B.V. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| GenTLE NCT06063850 |
P1/2 | Recruiting | Mesial Temporal Lobe Epilepsy | 12 | 2026-11-30 |
| AMT-191 NCT06270316 |
P1/2 | Recruiting | Fabry Disease | 20 | 2027-12-01 (+8 mo) |
| intra-striatal rAAV5-miHTT NCT05243017 |
P1/2 | Active, not recruiting | Huntington Disease | 14 | 2029-03 (+24 mo) |
| intra-striatal rAAV5-miHTT NCT04120493 |
P1/2 | Active, not recruiting | Huntington's Disease | 43 | 2029-06 (+78 mo) |
| AMT-162 NCT06100276 |
P1/2 | Active, not recruiting | Amyotrophic Lateral Sclerosis | 20 | 2030-12-30 (+54 mo) |